3-Methyladenine (3-MA)

Catalog No.S2767 Synonyms: NSC 66389

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.

Size Price Stock Quantity  
USD 70 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 106 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Targets
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D NX;3WpFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHEXWQ{dU1? MoLuNog> NXnJWIpYTE2VTx?= NWDwOpVRemWmdXPld{Boem:5dHigbY5pcWKrdH;yfUBm\m[nY4Sgc4YhSkSPQx?= NWP5bWhXOjV5MU[1OlE>
A549  M2nCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\hWVl{O22P MWKybC=> M{jrcGROW09? NHTKbmZz\WS3Y3XzJIdzd3e2aDDpcohq[mm2b4L5JIVn\mWldDDv[kBDTE2F Mnz4NlU4OTZ3NkG=
95D M3zocmFxd3C2b4Ppd{BCe3OjeR?= MojJOY1O MYSybC=> NX;tcm5QTE2VTx?= MUnpcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh? NIroTpQzPTdzNkW2NS=>
A549  MlfmRZBweHSxc3nzJGF{e2G7 MVK1cW0> MmnWNog> MkLsSG1UVw>? MlmxbY5pcWKrdIOgRmROSy2rbnT1Z4VlKGGyb4D0c5Rq[yClZXzsJIRm[XSq NUnFdGIyOjV5MU[1OlE>
NBL-W-S  M13OdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy0clcxOW2P Mn;ZOog> MVjlcohidmOnczDHRW5VNTZzIITvfIlkcXS7 MmnkNlU{OjN{MkK=
NBL-W-S  Ml3yRZBweHSxc3nzJGF{e2G7 NYm0[mFMOW2P NGXaOVM3cA>? NHPjfWVqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBISU6WLU[x NVn1UY5WOjV|MkOyNlI>
A2780cp  NVew[3N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDINY1O NWrnZnpxOWh? M1LVN4lv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp MV6yOVMzOjZ7NB?=
A549  MV7GeY5kfGmxbjDBd5NigQ>? NH7HeIs2dU1? NVzqdHgzOmh? NULMWpFZe3WycILld5NmeyCVUFOgbY5lfWOnZDDhZ4N2dXWuYYTpc44hd2ZiTFOzMWlK MVKyOVI5PTZ{OB?=
H157 MmraSpVv[3Srb36gRZN{[Xl? MUe1cW0> Ml7GNog> M4Hi[ZN2eHC{ZYPz[ZMhW1CFIHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEyFMz3JTS=> MoDTNlUzQDV4Mki=
MDR NXzOXXBRSXCxcITvd4l{KEG|c3H5 NVzBOHVuOTCvTR?= MkfrOog> NF;GTY1{fHKnbnf0bIVveyC2aHWgdI94\XJib3[gZY51cWOjbnPldkBlenWpcx?= M1;jd|I2ODF7N{Cx
HT-29  NUDBSJdDSXCxcITvd4l{KEG|c3H5 MY[xcW0> MY[0PIg> MlT3SG1UVw>? M2j2T4VvcGGwY3XzJIJwenSnen;tbYIucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ NXLPcXJnOjR6NEKxOVg>
Microglia  M4nRO2Fxd3C2b4Ppd{BCe3OjeR?= MnLSOY1O NF7KcmEzPGh? M2DVPIRm[3KnYYPld{BpgXCxeHnhMYlv\HWlZXSgZ4VtdCCmZXH0bC=> M3\NdVI1QDF6NkCx
A2780cp NFm3cFFCeG:ydH;zbZMhSXO|YYm= Mmf2Nk42dU1? M3XXVVFp Ml\U[IRJOk9? MmrE[Y5p[W6lZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MXiyOFgyPzl2Nh?=
HepG2 NVr1[3Z[TnWwY4Tpc44hSXO|YYm= MnfwOY1O MVi0bC=> NGXoSYRqdmO{ZXHz[ZMhUExicnXs[YF{\Q>? M2jlWVI1PzF|NUi3
A549 MWjBdI9xfG:|aYOgRZN{[Xl? M4TJflVuVQ>? NXm0W5YxPDiq NILXVlVl\WO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubDDk[YF1cCCjbnSg[ZhxemW|c3nvckBt\X[nbIOgc4Yh[2G|cHHz[U0{NCCEZXPsbY4uOSCjbnSgUGM{NUmL MmLJNlQ4ODZ|MEO=
U2OS NHji[pBCeG:ydH;zbZMhSXO|YYm= MVWxNI1O MV2yOIg> MYHpcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[geIhmKFV{T2OgZ4VtdHNiaX7keYNm\CCkeTDEc5g> NF\Tc3QzPDZ|OUCxNy=>
Saos-2 NYjGcHc2SXCxcITvd4l{KEG|c3H5 NGD2e4gyOG2P Mke1NlRp NHP1O41qdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gc4YhfGinIGWyU3Mh[2WubIOgbY5lfWOnZDDifUBFd3h? NHzTTmIzPDZ|OUCxNy=>
A549 M{XsXGFxd3C2b4Ppd{BCe3OjeR?= MlrLNVBuVQ>? M4q4e|Q5cA>? NIS3Vo5i[2OnbHXyZZRmeyC2aHWgdoVlfWO2aX;uJI9nKGOnbHygeoli[mmuaYT5JIlv\HWlZXSgZpkhWFS[ M1G3cVI1PjJ4N{Ky
HCT116  MonwRZBweHSxc3nzJGF{e2G7 M133c|VuVQ>? MmW2NlRp NGjaeJJmdmijbnPld{B1cGViYYDvdJRwe2m|IHnu[JVk\WRiYomgZZBq\2WwaX6= M1PmRlI1PjJ4NUKy
HGC-27 M{X6W2Z2dmO2aX;uJGF{e2G7 Mk\2NVBuVQ>? NIC2fYQycA>? M4DZWYlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBtd3O|IHL5JHJCTDByMTDvdkBOUy1{MkC2 MXWyOFQyPjN2OR?=
U2OS  MYPGeY5kfGmxbjDBd5NigQ>? M4Djd|AvPS9zbV2= MoO3OFhp M1WyW4lv\HWlZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ NYj4c4J[OjR|NUizOFI>
MG-63 NXzGU4lqTnWwY4Tpc44hSXO|YYm= MYewMlUwOW2P MnP4OFhp M{j6OYlv\HWlZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ NG\FemozPDN3OEO0Ni=>
MG-63 M3m1SGFxd3C2b4Ppd{BCe3OjeR?= MlXCNE42NzGvTR?= M4HmUlMzcA>? NIDyN49mdmijbnPld{B{[Wyrbn;tfYNqdi2rbnT1Z4VlKGOnbHygZZBweHSxc3nz MkXGNlQ{PTh|NEK=
MG-63 M2DhcmFxd3C2b4Ppd{BCe3OjeR?= MoS3NVBuVQ>? NXz2d|NFOTKq MYnlcohidmOnczDEVE1qdmS3Y3XkJIFxd3C2b4Ppdy=> NYq3VXk1OjR|NUizNFE>
NTUB1 NI\XTIlCeG:ydH;zbZMhSXO|YYm= Ml3mOY1O NUC1b2xiOS53aB?= MlzGdI91\W62aXH0[ZMh[2WuZXPvfIljNWmwZIXj[YQh[XCxcITvd4l{ MXWyOFM1QTF5Nh?=
T24 NVWwUo1vSXCxcITvd4l{KEG|c3H5 MWi1cW0> NVLpZohWOS53aB?= MVvwc5RmdnSrYYTld{Bk\WynY3;4bYIucW6mdXPl[EBieG:ydH;zbZM> MXOyOFM1QTF5Nh?=
SGC-7901  MmO1RZBweHSxc3nzJGF{e2G7 NYi2[4tOOm2P MYKxbC=> MVHpcoNz\WG|ZYOgR2EuPCCrbnT1Z4VlKGGyb4D0c5Nqew>? NGixSmIzPDN{MUO0NC=>
SMMC-7721 MkO3RZBweHSxc3nzJGF{e2G7 MUOycW0> NYnFe3JYOWh? NUnWOmRYcW6lcnXhd4V{KEODLUSgbY5lfWOnZDDhdI9xfG:|aYO= NXG0XlJ3OjR|MkGzOFA>
ECSCs  NYrObmtSSXCxcITvd4l{KEG|c3H5 NHjjcmgyOG2P MYi0bC=> M1G1TIRm[3KnYYPld{Bz[XCjbYnjbY4ufHKnYYTl[EBieG:ydH;zbZM> NV\tVZZEOjR|MUmxNFk>
MCF-7  M{HXV2Z2dmO2aX;uJGF{e2G7 NWjHZpk2OTCvTR?= MVqyOIg> M2HC[4lvcGmkaYTzJJRp\SCjdYTvdIhi\3liaX7keYNm\CCkeTDjbIVud3SqZYLhdJkh\HK3Z4O= M{DF[FI1OzF3NUe4
UOK257 MYXBdI9xfG:|aYOgRZN{[Xl? MnvhOY1O M1LzNVNp MWPlcohidmOnczDwZYNtcXSjeHXsMY1m\GmjdHXkJIFxd3C2b4Ppd:Kh M1j6ZlI1OzB3NkC0
ACHN-5968 NX32V2hqSXCxcITvd4l{KEG|c3H5 M4Gy[|VuVQ>? NFXQS5M{cA>? NFP4cHlmdmijbnPld{Bx[WOuaYThfIVtNW2nZHnheIVlKGGyb4D0c5Nqe8Li MnrSNlQ{ODV4MES=
Huh7 NH3rV5JCeG:ydH;zbZMhSXO|YYm= MkLZNo1O MWmxNog> NFLBOW9FVVOR MW\pcohq[mm2czDBXmQ5ODV3LXnu[JVk\WRiY3XscEBl\WG2aB?= NWT2RVNxOjR{OUezNFA>
Hep3B M4C3bmFxd3C2b4Ppd{BCe3OjeR?= MWKycW0> M1XaXVEzcA>? MorySG1UVw>? MXPpcohq[mm2czDBXmQ5ODV3LXnu[JVk\WRiY3XscEBl\WG2aB?= NITVPHQzPDJ7N{OwNC=>
RKO NYLPSZhsTnWwY4Tpc44hSXO|YYm= NGniXIYzdU1? MV2xbC=> Mk[wSG1UVw>? MkPi[Y5p[W6lZYOgZ4VtdCCmZXH0bEBjgSCpZXzkZY5idXmlaX6= NIrh[ogzPDJ7MUe3Oy=>
HepG2 E47 MknvSpVv[3Srb36gRZN{[Xl? NFG2elQzNjWvTR?= M2TaS|Q5cA>? MkSxbY5kemWjc3XzJJRp\SC2b4jpZ4l1gSCxZjDBRUwhSlORLDDhcoQhS0OuNB?= NIPrcWczPDJ5M{ezPC=>
LoVo  MknlRZBweHSxc3nzJGF{e2G7 NUTBUnNyPW2P NYO4SIh7PDiq M4TTXoVvcGGwY3XzJGRESS2rbnT1Z4VlKGGyb4D0c5Nqey5? NILPcFEzPDJyMUixNi=>
WiDr NFS4VotHfW6ldHnvckBCe3OjeR?= NFzHdYYyOG2P M1XwbVFp NXTQVYZWcW6qaXLpeJMhWEOETD3pcoR2[2WmIFzDN{BKUSCneIDy[ZN{cW:w MnHWNlQyQTB2OEm=
H1299  NVnXXVlQTnWwY4Tpc44hSXO|YYm= NX\WenEzOTCvTR?= NUjMbIdMPGh? NUKx[lY5cW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? M4nxTVI1OTd|MkC4
H460 M1noOmZ2dmO2aX;uJGF{e2G7 NGnWWGUyOG2P NXvBPIpSPGh? MUfpcoNz\WG|ZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> M2G1UFI1OTd|MkC4
A549 M1yxVmZ2dmO2aX;uJGF{e2G7 NY\4WIVDOTCvTR?= MYK0bC=> NXf5OZRQcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliaYLyZYRq[XSrb36= NFH5SJYzPDF2MkezOS=>
Hep3B MljRRZBweHSxc3nzJGF{e2G7 MUm1cW0> MUKyOIg> NGjhNmtifHSnboXheIV{KFSQRj5OtUBxem:2ZXP0bY9vKGGpYXnud5Qhe2W{dX2gd5Rien[jdHnvck1u\WSrYYTl[EBieG:ydH;zbZM> MVeyOFA3PjZ7Mx?=
SMMC-7721 NXTmfmtGSXCxcITvd4l{KEG|c3H5 NUjUenhPPW2P NIDVWlgzPGh? NH\5cmVifHSnboXheIV{KFSQRj5OtUBxem:2ZXP0bY9vKGGpYXnud5Qhe2W{dX2gd5Rien[jdHnvck1u\WSrYYTl[EBieG:ydH;zbZM> Mn;1NlQxPjZ4OUO=
HO8910 M2L5[mFxd3C2b4Ppd{BCe3OjeR?= MW[xNI1O M2rlflEzcA>? M3HmRoVvcGGwY3XzJGIyQS2rbnT1Z4VlKGGyb4D0c5Nq M1nNbFI{QTh|NkGw
MCF7 NWCxeW9oTnWwY4Tpc44hSXO|YYm= NGLGNWY2dU1? NWnRZYhTOjSq M1vyTIlv[3KnYYPld{BEfU9iaX7keYNm\CClZXzsJIRm[XSq NFLHZXczOzl4Mk[yPS=>
HONE-1  MlPNSpVv[3Srb36gRZN{[Xl? NVH2e3F3PW2P MVWxbC=> M2ToWZJmeHKnc4Pld{A3ei2vZXTpZZRm\CCUT2OgdJJw\HWldHnvci=> MoTxNlM5QTJ|NUi=
HeLa NGnzWJRHfW6ldHnvckBCe3OjeR?= M2rHclExdU1? M1\oWFJp NGSzU4t{fXCycnXzd4V{KEyFMzDJTUBmgHC{ZYPzbZNwdg>? NVK2dIhJOjN6NkS3N|g>
HepG2 MXrGeY5kfGmxbjDBd5NigQ>? M1LmVVExdU1? M{eyVFI1cA>? MlG3bY5pcWKrdIOgd4lVUUeDUj2gZY5lKEiEU2OtbY5lfWOnZDDheZRweGijZ4m= MV6yN|gyPzB2MB?=
SH-SY5Y NXHlWJBITnWwY4Tpc44hSXO|YYm= NFPudXAydU1? MXmyOIg> MmHpbY5pcWKrdIOgeIhmKGG3dH;wbIFogSCrbnT1Z4VlKGK7IGTPR3A> MlSzNlM4PDNzNEi=
SH-SY5Y NUmxdJJbSXCxcITvd4l{KEG|c3H5 NF;QdpI2dU1? MYixbC=> M3;iR4Fjd2yrc3jld{Bk\Wyjc4Tyc4whdmW3cn;wdo91\WO2aY\lJIVn\mWldB?= MVeyN|YyQTN7NR?=
PC12  M4D6TWZ2dmO2aX;uJGF{e2G7 NFT1cHgyOG2P NYHG[HFYOjSq NGjBVXR4[XSnch?= MVhCpIlvcGmkaYTzJINpgW2xdIL5dJNqdi2uaXvlJJBzd3SnYYPvcYFtKGGldHn2bZR6Ng>? MX[yN|YxOzl5OR?=
OV2008 NYDDTmhtSXCxcITvd4l{KEG|c3H5 NF:zSVg2dU1? M{[wNVI1cA>? M1Ln[oNwdn[ncoTzJGZVYTd{MDD3bZRpKEOGRGCgbY51dyCjbjDh[IRqfGm4ZTDl[oZm[3RidH;3ZZJleyCtaXzsbY5oKG:4YYLpZY4h[2GwY3XyJINmdGy| M3G4ZlI{PTl{Mkix
A2780 NX;UbJZ2SXCxcITvd4l{KEG|c3H5 MmfvOY1O M2fZWFI1cA>? MWLjc453\XK2czDGWHk4OjBid3n0bEBETESSIHnueI8h[W5iYXTkbZRqfmViZX\m[YN1KHSxd3Hy[JMhc2mubHnu[{BwfmG{aXHuJINidmOncjDj[Yxtew>? MX[yN|U6OjJ6MR?=
Saos-2  MkDQRZBweHSxc3nzJGF{e2G7 NFruR5QydU1? NUXpcFVEQT[q M2[3OIlv[3KnYYPld{Bk\WyuIHTlZZRpKGmwZIXj[YQh[nliUFPY NHL5TpQzOzV4M{G3NS=>
1321N1 NGjQZWZEgXSxdH;4bYNqfHliQYPzZZk> NFL6b2U2dU1? NIO1TYwzPGh? MkLMdJJwfGWldIOgZ4VtdCCjZ3HpcpN1KFCFTj3pcoR2[2WmIITvfIlkcXS7 NInU[|czOzV{NUK2OS=>
SH-SY5Y M3;IeWN6fG:2b4jpZ4l1gSCDc4PhfS=> NGHRXIE2dU1? NF7sd4wzPGh? MXTpcoNz\WG|ZYOgVGNPKHSxeHnjbZR6 MYmyN|UzPTJ4NR?=
HT-29  MkC1SpVv[3Srb36gRZN{[Xl? M1G5O|FuVQ>? Mn7sOFgwQT[q MUHpcohq[mm2czDBUXBMKGmwZIXj[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq MWSyN|UxQDJ5Mh?=
OR6 MXrGeY5kfGmxbjDBd5NigQ>? NGDYXXkyOG2P NHT0UJc4Omh? MVrzeZBxemW|c3XzJGhEXiC{ZYDsbYNifGmxbjDhcoQh\m:{bXH0bY9vKG:oIHH1eI9xcGGpb4PvcYV{ Ml;oNlM{QTV6N{W=
Hela  NXfsfJdZTnWwY4Tpc44hSXO|YYm= NGr3XFE2dU1? Mn;6NlRp MXPpcohq[mm2czDzeIFzfmG2aX;uMYlv\HWlZXSgZZV1d3CqYXf5 NYHpemZQOjN|OUW2O|k>
MCF-7  MnmySpVv[3Srb36gRZN{[Xl? MkHlOY1O MXqyOIg> MUPpcohq[mm2czDzeIFzfmG2aX;uMYlv\HWlZXSgZZV1d3CqYXf5 NGrxVWkzOzN7NU[3PS=>
HUVECs MUPGeY5kfGmxbjDBd5NigQ>? MVGzcW0> M3eySVI1cA>? MmqyZoxw[2u|IITo[UBxem:2ZXP0bZZmKGWoZnXjeEBw\iC{ZYP2[ZJifHKxbDDifUBqdmirYnn0bY5oKGG3dH;wbIFogQ>? M324OFI{OzV6OUK4
T24 NIHlbpdHfW6ldHnvckBCe3OjeR?= NHnkNGoyOG2P NXr2NGk{OWh? MnLFdoVlfWOnczD0bIUh[2ynYY\h[4Uhd2ZiTFOzJIFnfGW{IHLhbYNidGmwIITy[YF1dWWwdB?= NYTWSlVFOjN|NUSwPFA>
U251MG  Mny0SpVv[3Srb36gRZN{[Xl? MU[zcW0> NVHHSXlxOWh? MnHHd5VxeHKnc4Pld{BNSzNvSVmgdJJwfGWrbjDlfJBz\XO|aX;u Ml;oNlM{Ozh4MUi=
GTL-16  MWPBdI9xfG:|aYOgRZN{[Xl? NEPMTYI2dU1? NXfBOWo4OjSq NIHXRlRz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHzJINwdXCjcnXkJJRwKGOnbHzzJJRz\WG2ZXSge4l1cCCPRWSgbY5pcWKrdH;ydy=> M3LIb|I{OzF|NEmw
T-47D MkmySpVv[3Srb36gRZN{[Xl? NYnuOnVzOTCvTR?= MlTLNog> MVXpcohq[mm2czDheZRweGijZ4mgdJJw[2W|czDhcoQhcW6lcnXhd4V{KHKjcHHtfYNqdiCrbnT1Z4VlKGGyb4D0c5Nqew>? MkHNNlM{ODByMk[=
PaCa44 MV3BdI9xfG:|aYOgRZN{[Xl? NIn0PI0zNjWvTR?= MkK0NYg> NXq4U3NUemWmdXPld:Kh\2WwaYDpck1u\WSrYYTl[EBieG:ydH;zbZM> MWCyN|EzPDFzMh?=
MDA-MB231 MVHGeY5kfGmxbjDBd5NigQ>? NXnwbXdtPW2P MmDtNYg> NX;EVoJVcW6lcnXhd4V{KHKnc4\ldoF1em:uLX3l[IlifGWmIHPhd5Bie2ViYXP0bZZifGmxbjDhcoQh[2WubDDk[YF1cA>? NV\xXY1JOjNyOEi4OVA>
HeLa MVzBdI9xfG:|aYOgRZN{[Xl? MkPYNVBuVQ>? MmX0Nog> Mn7N[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHPvMZRz\WG2bXXueEB4cXSqIGDFTS=> NUX6fINoOjNyMECxN|U>
SK-HEP-1 MUHBdI9xfG:|aYOgRZN{[Xl? MVuxNI1O MkC0NYg> NWXmSohweHKxdHXjeJMh[WejaX7zeEBifXSxcHjh[5kh[W6mIHnu[JVk\XNiYYDvdJRwe2m|IHnuJIJ2\mGuaX6teJJm[XSnZDDj[Yxtew>? NXzCNYNSOjJ6NUi2OFk>
HepG2 NUSwUnE{SXCxcITvd4l{KEG|c3H5 M3fjPFNuVQ>? M4ntWlVp MUHy[YR2[2W|IHPlcIwh[XCxcITvd4l{KGmwZIXj[YQh[nliUVTz MnjLNlI5OzZ3OUW=
MCF-7  Mk\KSpVv[3Srb36gRZN{[Xl? NV\OfXl6Om2P M1TFRlI1cA>? NV3WNIFKcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> MWOyOFk4ODZ5Nh?=
MDA-MB-231 Ml63SpVv[3Srb36gRZN{[Xl? NET6SlEzdU1? NHv5TWszPGh? NV[zZotFcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> MXKyOFk4ODZ5Nh?=
MCF-7  M1Gw[WZ2dmO2aX;uJGF{e2G7 MXyycW0> Mo\EOFhp M33K[pBzd22xdHXzJHRONWmwZIXj[YQh[2WubDDk[YF1cA>? MoTGNlQ6PzB4N{[=
MDA-MB-231 MXvGeY5kfGmxbjDBd5NigQ>? MoD6No1O NHHyXZo1QGh? NUfLb5BpeHKxbX;0[ZMhXE1vaX7keYNm\CClZXzsJIRm[XSq MXWyOFk4ODZ5Nh?=
PANC-1  Ml3BRZBweHSxc3nzJGF{e2G7 MnPMNY1O NELxd4s1QGh? M3vmT2ROW09? MmfW[Y5p[W6lZYOgZo9zfGW8b33pZk1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> NXnvVJlGOjR6NEKxOVg>
MDA-MB 231 M4Xa[GFxd3C2b4Ppd{BCe3OjeR?= M{nMT|VuVQ>? Mo\jNE42cA>? NEnvNYFud2S3bHH0[ZMhXG:lb33pcuKvyqCrbnT1Z4VlKGGyb4D0c5Nqew>? NHPsWG0zPDh|MEe4NS=>
Microglia  NW\1Zo1YSXCxcITvd4l{KEG|c3H5 MnK5OY1O NWn2VYRqOjSq NHn4PWZl\WO{ZXHz[ZMhcHmyb4jpZU1qdmS3Y3XkJINmdGxiZHXheIg> NGThWYMzPDhzOE[wNS=>
A2780cp NXTrTIg6SXCxcITvd4l{KEG|c3H5 MUmyMlVuVQ>? NWHITG1vOWh? MmjS[IRJOk9? NGXZe2RmdmijbnPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp MkH2NlQ5OTd7NE[=
HepG2 NUjCNIRjTnWwY4Tpc44hSXO|YYm= NH3rSpY2dU1? NGnNdYM1cA>? Mlz3bY5kemWjc3XzJINmdGy3bHHyJIxmfmWuczDv[kBJVMLi NHjMe4MzPDdzM{W4Oy=>
U2OS MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDBNVBuVQ>? Ml6yNlRp M4LUc4lvfGWwc3nmbYV{KHSqZTDndo94fGhiaX7obYJqfGmxbjDpcoR2[2WmIHL5JGRwgA>? NWn2SGYzOjR4M{mwNVM>
HCT116 NWDmUIlMSXCxcITvd4l{KEG|c3H5 NVnrVldYPW2P NXLx[JVwOjSq MnHiSG1UVw>? M3G2[IVvcGGwY3XzJIFxcWenbnnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MojxNlQ3OjZ3MkK=
MCF-7  NHn4NXJCeG:ydH;zbZMhSXO|YYm= M3S3VVAvOW2P NUDZNFFsPmh? MkD6[Y5p[W6lZYOgd4lzfGmwb3ytbY5lfWOnZDDhdI9xfG:|aYO= NUHScWdwOjJ5NUG5PFk>
PC-3  NIrTSYJCeG:ydH;zbZMhSXO|YYm= MmnLNo1O MlK2Nog> NULO[Io{cW6lcnXhd4V{KE:UST3pcoR2[2WmIHPlcIwh\GWjdHi= NV3zXnZNOjJ5NEW1PFA>
U251  Mk[0RZBweHSxc3nzJGF{e2G7 NIXO[|Y2dU1? MYKyOIg> NFm3NYdqdmO{ZXHz[ZMhWzFvaX7keYNm\CClZXzsJIRm[XSq NXPuXHZEOjJ3N{m3PFg>
HeLa  Mnz1RZBweHSxc3nzJGF{e2G7 M2LwPFVuVQ>? MnTQNlRp MUDpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHPlcIwh\GWjdHi= NGXleWwzOjV2NUGyPC=>
A549 MXvGeY5kfGmxbjDBd5NigQ>? MmDCNE4ydU1? M2\oRVI1cA>? NVSy[IlJe3WycILld5NmeyCVVUGxNlc1NWmwZIXj[YQh[2WubDDk[YF1cA>? MUOyNlQ3Pjl4MB?=
pDCs NFLJOFJHfW6ldHnvckBCe3OjeR?= NWPjWnBuOTCvTR?= MmjjNE42cA>? MV5CpJJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDJSm4u|rFiYomgd5NTVkF2MB?= MWWyNlM6PjV7OR?=
BGC-823 NYL0dIpITnWwY4Tpc44hSXO|YYm= MYG1cW0> MkTKNog> MonQbY5pcWKrdIOgeIhmKHKjdHWgc4Yh[XW2b4DoZYdq[yClZXzsdy=> NUfnR25OOjJ|MkKxOVI>
U937 MYjGeY5kfGmxbjDBd5NigQ>? NVHVfmd5Om2P M1:0XlEzcA>? NWnp[YZT\GWlcnXhd4V{KHSqZTDheZRweGijZ4mgdoF1cW0EoB?= M37HXVIzOTV3MUWw
Marc-145 MlX5SpVv[3Srb36gRZN{[Xl? MXS1cW0> MVyxNk8zPC9|Nni= NHK5[lZz\WS3Y3XzJJRp\SCSUmLTWkB1cXSncoOgZY5lKHSqZTDwdo91\WmwIHX4dJJme3Orb36= NV\6WI5yOjJzMUm5NFA>
HBx  M3q5SGFxd3C2b4Ppd{BCe3OjeR?= NVnTOIdoOTCvTR?= NVzX[ms4PDiq MVXEUXNQ M{jDe4lv[3KnYYPld{Bk\WyuIHTlZZRp Mm\YNlIxOjByN{i=
MCF-7 MU\GeY5kfGmxbjDBd5NigQ>? MUexNI1O NGrnRZY1QGh? NWK0VZlM[myxY3vzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KGKxcoTlfo9ucWJ? M2jsS|IyQTNzOUO3
RMPI8226  MUjGeY5kfGmxbjDBd5NigQ>? NWW3VYk{PW2P NHzZOIIycA>? NFLTNYZ{fXCycnXzd4V{KHSqZTDs[ZZmdCCxZjDheZRweGijZ4mgeY5l\XJiboX0dolmdnRiZHXwcIV1cW:w MoPoNlE6OTV4MkC=
PC12/TetOn NYPDUIx7TnWwY4Tpc44hSXO|YYm= MoTENE4yNzGvTR?= NHHOeFUyQGh? NU\D[|A4dGWjZIOgeI8h|rFvc4nuLHdVMSCjY3P1cZVt[XSrb36sJJRwgGmlaYT5MEBidmRib3zp[49u\XJiZn;ycYF1cW:wwrC= NFy0S5ozOTlyNk[1PS=>
HeLa  MVPDfZRwfG:6aXPpeJkhSXO|YYm= MnLwNo1O M{nPN|I1cA>? NXnR[pd4cW6qaXLpeIV{KHSqZTDjfZRwfG:6aXPpeJkhd2Zic3nsbYJqdmmwIITvJGhmVGFiY3XscJMv MUWyNVg4PTN6NR?=
Jurkat MVTGeY5kfGmxbjDBd5NigQ>? M3fGNlExdU1? MWqxbC=> M2[wfIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzNvSVmgZY5lKHSqZTDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= M4HyelIyQDZ2MEO3
K562 NFHrW4pHfW6ldHnvckBCe3OjeR?= M2HI[FExdU1? NYXCT|l5OWh? Ml3S[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEOy2LSTDhcoQhfGinIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= MWKyNVg3PDB|Nx?=
Nara-H NETZTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ztOVVuVQ>? NHz3T5M1QGh? MVTlcohidmOnczD0[Y1{cXKxbHnteZNu\WSrYYTl[EB{fXCycnXzd4lwdiCxZjDOZZJiNUhiY3XscEBxem:uaX\ldoF1cW:w MXKyNVgxPTB|Mx?=
HUVECs MYnGeY5kfGmxbjDBd5NigQ>? Mmm1NVBuVQ>? M4\ke|AvPWh? NWrEbW44\GWlcnXhd4V{KHSqZTDBS2UuSlODaX7keYNm\CCjdYTvdIhi\3libHX2[S=> MVWyNVQ3QDV7Mh?=
HepG2 M2HuV2Fxd3C2b4Ppd{BCe3OjeR?= NWTXWY1tOm2P MYWxbC=> MnH4[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NFfiWokzOTR3M{[5NS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
α-SMA / TGF-β / LC-3BI / LC-3B II / Beclin-1 / NF-κB p65; 

PubMed: 29296191     


Western blotting analysed expression of α-SMA, TGF-β, LC-3B, Beclin-1, NF-κB and NF-κBp65 in hepatic stellate cells.

caspase-3 / caspase-9 / PARP; 

PubMed: 25891159     


EC9706 cell lysates were prepared and subjected to immunoblotting with antibodies against caspase-3, caspase-9 and PARP. The expression ratios in each experiment were determined densitometrically. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; PI, propidum iodide; PARP, poly(ADP ribose) polymerase.

VEGF; 

PubMed: 25891159     


Effects of autophagy inhibition on the protein expression levels of VEGF. Western blot analysis demonstrated that VEGF protein expression levels were decreased when the EC9706 human esophageal squamous cell carcinoma cells were treated with 3-MA. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; VEGF, vascular endothelial growth factor.

APP / BACE1 / ADAM17 / Presenilin 1 / Presenilin 2 / Nicastrin / APH-1 / Pen-2 / LC3-1 / LC3-2; 

PubMed: 26316755     


Presenilin 1, Nicastrin, and Pen-2 were increased with the 3-MA treatment (*P<0.001) while the other component of the γ-secretase complex (APH-1 and Presenilin 2) has no difference. 3-MA, 3-methyladenine; Con, control; APP, amyloid protein precursor.

29296191 25891159 26316755
Immunofluorescence
LC3 / Hif-α / COX2; 

PubMed: 29039446     


Chemical interventions of autophagy and ischemic-hypoxic injury, assessed using immunochemical double labeling. Compared with the control group, expression levels of HIF-α and COX2 were altered by chemical intervention. (A) Chemical intervention altered the expression of HIF-α and autophagosmes. Following autophagy antagonist (3-MA) intervention, expression of HIF-α was enhanced, compared with that in the OGD group, and was decreased by the autophagy agonist, rapamycin. In the MHY treatment group, expression of HIF-α was similar to that in the 3-MA group. (B) Chemical intervention showed changes in the expression of COX2 and autophagosomes. Changes in the expression of COX2 were similar to changes in HIF-α. Scale bar, 30 µm. OGD, oxygen-glucose deprivation; HIF-α, hypoxia-inducible factor-α; COX2, cyclooxygenase 2; 3-MA, 3-methyladenine; RP, rapamycin; MHY, MHY1485.

29039446
Growth inhibition assay
Cell viability; 

PubMed: 26934124     


KYSE 180 cells were co-treated with EDHB (40 μg/ml) and various concentrations of 3-MA for 24 h (left) or 48 h (right), and cell viability was determined by WST-8 assays.

26934124
In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay:[4]
+ Expand

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:[2]
+ Expand
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research:[5]
+ Expand
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Formulation: Saline
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5

CAS No. 5142-23-4
Storage powder
in solvent
Synonyms NSC 66389

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • Answer:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID